Peptide Schedule
Melanotan I13 residues (approx.)SYSMEHFRWGKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Melanotan I Dosage Calculator
Melanotan I (afamelanotide) is a synthetic 13-amino-acid peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH).
500mcg · Daily
Summary: Add 2mL BAC water to your 10mg vial. Draw to 10.0 units on a U-100 syringe for a 500mcg dose. This vial will last 20 doses.
Cycle Planner
Melanotan I Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~15 hours (implant)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Melanotan I Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Daily |
| Moderate | 1mg | Daily |
| Aggressive | 1,500mcg | Daily |
Note: FDA-approved as Scenesse (16 mg subcutaneous implant) for erythropoietic protoporphyria (EPP). Scenesse implant administered every 60 days by a healthcare provider. Injectable research-grade melanotan I uses lower SC doses (0.5-1.5 mg daily). More MC1R-selective than Melanotan II with fewer sexual side effects.
About Melanotan I
Melanotan I (afamelanotide) is a synthetic 13-amino-acid peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). It is the first and only FDA-approved melanocortin receptor agonist for increasing sun tolerance. Sold under the brand name Scenesse, it received FDA approval in October 2019 for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder where patients experience severe phototoxic reactions to sunlight due to excess protoporphyrin IX accumulation. Unlike its shorter cousin Melanotan II, which activates multiple melanocortin receptor subtypes and produces sexual arousal, appetite suppression, and unpredictable side effects, Melanotan I is a selective MC1R agonist. This selectivity means it drives eumelanin production in melanocytes without the broad off-target effects seen with less selective analogs. The result is a genuine increase in brown-black eumelanin pigment that absorbs UV radiation and dissipates it as heat, providing real photoprotection from the inside out. In Phase 3 trials involving 168 EPP patients across the EU and US, afamelanotide-treated patients tolerated significantly more pain-free sun exposure (median 6.0 hours vs 0.8 hours in placebo, p=0.005) and experienced fewer phototoxic reactions (77 vs 146, p=0.04). In the research peptide community, injectable melanotan I is used at much lower doses (0.5-1.5 mg daily SC) for cosmetic tanning. Its superior MC1R selectivity and cleaner side effect profile make it a preferred option for users who want pigmentation changes without the nausea, flushing, or sexual effects associated with Melanotan II.